AGP Executive Report
Last update: 7 hours agoSpecialty Pharma Tariff Relief: The US Commerce Department published a list of countries, including Liechtenstein, eligible for zero tariffs on specified specialty pharmaceutical products and ingredients ahead of 100% Section 232 duties starting September 29—covering areas like orphan drugs, gene and cell therapies, and certain medical countermeasures. EU Industrial Policy Watch: Brussels’ proposed “Made in EU” procurement rules are drawing fresh criticism as protectionism in disguise, with local-content and low-carbon requirements aimed at strategic sectors like EVs, batteries, solar, wind, hydrogen and nuclear. Trade Deal Update: Brazil has formally incorporated the Mercosur–EFTA Free Trade Agreement, with preferential tariffs for Switzerland/Liechtenstein dependent on internal procedures. Biotech for the Region: The European Commission granted marketing authorisation for NEZGLYAL® (leriglitazone) for childhood cALD, the first pharmacological treatment for early intervention in the EU, with launches expected to start in Germany. Auto Market Signal: Chinese brands kept gaining in Europe in August, with BYD registrations more than doubling across the EU plus Iceland, Liechtenstein, Norway and Switzerland.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
